Open · HT942526ALSRPTDA · CFDA 12.420 · Discretionary
DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Open
- Status
- 48d
- Days left
- 6
- Expected awards
The verdict
DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award is an open discretionary opportunity from Defense Health Agency Contracting Activity - DHACA, offering Varies by applicant across 6 expected awards. Applications close in 48 days.
- Varies
- award range
- Open
- 48 days left
- 6
- expected awards
- 12.420
- CFDA program
Opportunity snapshot. This Grants.gov announcement - DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award - is cataloged under number HT942526ALSRPTDA and tied to CFDA assistance listing 12.420, posted by Defense Health Agency Contracting Activity - DHACA. Grants.gov currently shows the opportunity as open, first posted on May 4, 2026 and last updated on May 6, 2026. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. The agency has projected $12.0 million in total estimated funding for this announcement. It expects to issue 6 awards. If the agency funds the expected 6 awards from the $12.0 million estimated pool, the average award works out to roughly $2.0 million. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. Applications close on September 30, 2026 - roughly 48 days from today. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
September 30, 2026
Posted
May 4, 2026
Est. Total Funding
$12,000,000
Expected Awards
6
Instrument
Grant
Description
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems.Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.
Eligibility
Grants.gov lists this opportunity under eligibility category code 99. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |